The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Share News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 180.00
Bid: 175.00
Ask: 185.00
Change: -12.50 (-6.49%)
Spread: 10.00 (5.714%)
Open: 192.50
High: 192.50
Low: 177.50
Prev. Close: 192.50
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Beowulf raises funds for Kallak iron ore project

Mon, 04th Mar 2024 19:59

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

Beowulf Mining PLC - London-based mining company with projects in Sweden, Finland and Kosovo - Announces terms of previously announced fundraise. Says rights issue of Swedish depository receipts will raise up to GBP6.3 million, while a retail offer of ordinary shares in the UK will raise around GBP1.6 million. Notes the SDRs will be offered at SEK0.08 each and the shares at 0.61 pence each. Adds the SDRs will also be offered for subscription, without preferential rights, to institutional investors, other professional investors and the general public in Sweden. Beowulf says it has has received underwriting commitments for the rights issue for around 60% of the total. Explains proceeds will be used mainly to finance the continued development of the Kallak iron ore project in northern Sweden, including completion of the ongoing pre-feasibility study and environmental studies. Funds will also repay amounts advanced under the bridge loan financing arrangements, and corporate costs.

----------

Kefi Gold & Copper PLC - exploration and development company focused on gold and copper projects in the Arabian-Nubian Shield - Plans to raise GBP4.5 million placing at 0.6 pence per share. Further, issues 83.3 million shares to cover accrued fees to certain directors and advisers. In addition, launches retail offer at the same issue price. Explains funds will underpin the launch of the Tulu Kapi Gold project by mid-2024.

----------

LungLife AI Inc - California-based developer of clinical diagnostic solutions for early lung cancer detection - Plans to raise around GBP1.8 million via a GBP1.56 million placing at 35 pence each and a GBP250,000 subscription at the same price. Explains net proceeds, along with existing cash resources, are expected to be utilised to establish the commercial proof of concept of the company's LungLB test. Notes funding is expected to provide the company with a cash runway to early April 2025.

----------

RC365 Holding PLC - London-based company focusing on payment gateway solutions and IT support services - Enters into an unsecured convertible loan note with Mill End Capital Ltd for up to GBP4 million. Says net proceeds of the unsecured loan will be used for the continuing development of existing operations with a particular focus on expanding operations in Malaysia, Japan and the UK. States the first tranche of the CLN comprises GBP600,000, the second tranche a further GBP1.4 million. Any further tranche shall be at the written request of RC365 and discretion of the lender, but will not exceed GBP4 million, RC365 says.

----------

Faron Pharmaceuticals Ltd - Turku-Finland-based clinical-stage biopharmaceutical company - Announces binding commitments worth GBP3.2 million for convertible loans obtained from certain existing shareholders. Explains this allows it to make critical payments to third parties under agreed waivers with IPF. Says this secures its short-term financing needs until the end of March. Faron says talks continue to secure its short and longer-term financing needs, including first additional bridge financing of around EUR5 million. In addition to the short-term bridge financing, Faron intends to propose to the Annual General Meeting an authorization for a larger share issue. In total, Faron expects to need EUR35 million of financing to complete the enrolment of the phase 2 of the BEXMAB study and to obtain regulatory feedback from the US Food & Drug Administration. At February 19, notes cash and cash equivalents held by Faron totalled EUR4.3 million.

----------

Supernova Digital Assets PLC - looks to identify investment and business building opportunities in the Solana and crypto currency ecosystem - Plans return to shareholders. Intends to achieve this by purchasing its own shares through a tender offer. Further, raises GBP242,000 via placing at 0.1 pence per share.

----------

Celsius Resources Ltd - explorer focused on portfolio of copper-gold resources in the Philippines - Advises that trading will be halted on the Australian Securities Exchange effective from March 5 further to the company's request. Celsius says it requested the suspension ahead of an announcement in relation to its flagship Maalinao-Caigutan-Biyog copper-gold project and the issuance of project sensitive documents by the Philippine National Government. Says trading on the AIM market of the London Stock Exchange remains unaffected.

----------

Kibo Energy PLC - Galway, Ireland-based company with energy projects in Africa and the UK - Sells shares in its subsidiary Mast Energy Developments PLC worth GBP29,350. Notes proceeds will be used to pay down the balance balance on the bridge loan facility with RiverFort Global Opportunities PCC Ltd. Holds 33% stake in MED following the share sale.

----------

Braveheart Investment Group PLC - Dodworth, England-based investment company - Provides update on one of its investments, Paraytec Ltd. Notes Paraytec develops high performance specialist detectors for the analytical and life sciences instrumentation markets. In December, Braveheart sought a buyer for Paraytec, of which it owns 100%. But, notes it has been unable to secure an attractive offer and therefore decides to retain Paraytec within its portfolio.

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
12 Sep 2018 13:48

Faron Pharmaceuticals Says New Clever-1 Data Shows B Cell Response

LONDON (Alliance News) - Faron Pharmaceuticals Ltd said Wednesday that new data from its cell surface receptor Clever-1 showed B cell response control and humoral antibody production.The by

Read more
6 Sep 2018 16:01

UK Earnings, Trading Statements Calendar - Next 7 Days

Friday 7 September Secure Income REITHalf Year Results Ashmore GroupFull Year Year

Read more
21 Jun 2018 16:31

DIRECTOR DEALINGS: Faron Pharmaceuticals Directors Buy Shares

LONDON (Alliance News) - Faron Pharmaceuticals Oy said on Thursday several directors purchased shares over the course of three days from Tuesday to Thursday.On Tuesday, Non-Executive Matti

Read more
14 Jun 2018 11:30

Faron Pharmaceutics Reports Inconsistent Traumakine Biomarker Results

LONDON (Alliance News) - Faron Pharmaceuticals Oy on Thursday said preliminary biomarker data from its Traumakine phase III trial has produced inconsistent results.Faron is testing in a III

Read more
14 Jun 2018 11:00

WINNERS & LOSERS SUMMARY: Rolls Royce Flies High With Planned Job Cuts

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.----------FTSE 100 - up 2.6%. The jet engine maker said it will cut

Read more
24 May 2018 16:10

UK Shareholder Meetings Calendar - Next 7 Days

Friday 25 MayHochschild MiningFerrexpoKeywords Mutual (re managed 28 events 29 Stobart Life (re of

Read more
11 May 2018 08:45

Faron Says Traumakine Trial Did Not Produce Expected Results

LONDON (Alliance News) - Faron Pharmaceuticals Ltd said Friday that initial review of the Phase III trial for Traumakine drug used for the treatment of lung inflammation did not produce the seen a

Read more
8 May 2018 11:10

WINNERS & LOSERS SUMMARY: Virgin Money Gains On CYBG Takeover Offer

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Tuesday.----------FTSE 100 - up 4.1%. The Irish drugmaker said it has agreed

Read more
8 May 2018 10:17

Faron Pharmaceuticals Shares Dive As Traumakine Fails In Latest Test

LONDON (Alliance News) - Shares in Finnish firm Faron Pharmaceuticals Oy plunged on Tuesday as the company reported "extremely disappointing" results from its flagship Traumakine shares

Read more
8 May 2018 07:01

LONDON MARKET EARLY CALL: Stocks Called Lower As Iran Fears Boost Oil

LONDON (Alliance News) - Stock prices in London are seen opening lower on Tuesday following Monday's UK bank holiday as Chinese exports recovered at a faster pace in April amid concerns the US

Read more
1 May 2018 16:15

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 2 May Direct Line Insurance GroupQ1 ResultsConvaTec GroupQ1 GroupHalf

Read more
4 Apr 2018 12:53

Tiziana Appoints Leopoldo Zambeletti As Non-Executive Director

LONDON (Alliance News) - Tiziana Life Sciences PLC, a biotechnology company developing drugs for cancer and autoimmune diseases, said Wednesday Leopoldo Zambeletti has joined

Read more
9 Feb 2017 08:20

Faron Pharmaceuticals makes solid progress with drug programmes

(ShareCast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals updated the market on Thursday, ahead of its full year 2016 audited financial results which its board said will be announced on 29 March. The AIM-traded firm said for its Traumakine project, it expects to obtain the re

Read more
31 Oct 2016 12:44

Faron Pharma granted protection for IFN-beta by Finnish patent office

(ShareCast News) - Faron Pharmaceuticals' patent application to protect the intravenous use of interferon-beta, a cytokine protein, in a novel formulation has been accepted by the Finnish patent office that enables the company to build a global proprietary position for its Traumakine drug. The claim

Read more
24 Oct 2016 08:33

Faron Begins Recruitment For Japanese Phase 3 Traumakine Trial

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.